Company / Capital Expenditures
Atea Pharmaceuticals, Inc. Capital Expenditures History
FY2020-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.9M
FY2022
5-year range
$2.0K / $1.9M
FY2020-FY2022
Trend
+97050.0%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures changed +97050% YoY in FY2022, a notable deviation from the 2-year average annual change of +48483%.
Based on SEC 10-K filings.
$2M in FY2022.
Improved from $12,000 to $2M over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, capital expenditures increased 97050.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 10.30 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $1.9M | +97050.0% |
| FY2021 | $2.0K | -83.3% |
| FY2020 | $12.0K | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026